1. | eTruth | |
2. | user74399 | |
3. | parispenelope21 |
1. | eTruth | |
2. | user74399 | |
3. | parispenelope21 |
1. | user74399 03/14/2018 someone knew this |
2. | user74399 01/10/2019 La Jolla (LJPC) Stock Crashes -- Is There a Light at the End of the Tunnel? |
3. | user74399 03/07/2018 GIAPREZA™ (angiotensin II) Significantly Improved Survival and Reduced Time on Renal Replacement Therapy in Patients with Acute Kidney Injury |
4. | parispenelope21 03/22/2018 Announces that GIAPREZA (angiotensin II), injection for intravenous infusion, is now commercially available … |
5. | eTruth 08/09/2018 dang it, already bought a long time ago |
6. | eTruth 02/22/2018 ER |
7. | user74399 03/14/2018 La Jolla Pharmaceutical Company Announces $100 Million Public Offering of Common Stock |
8. | eTruth 03/14/2018 Announces $100 mln public offering of common stock |
9. | eTruth 02/21/2018 La Jolla Pharmaceutical Company Announces the Treatment of First Patient in GIAPREZA™ (angiotensin II) Pediatric Study |
10. | eTruth 02/26/2018 GIAPREZA™ (angiotensin II) Significantly Improved Survival of Patients with High APACHE II Scores in ATHOS-3 Study |